FAE Faes Farma, S.A.
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. The company also provides animal nutrition and health products. It offers products for various therapeutic areas. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Faes Farma (BME: FAE)
›
Faes Farma (BME: FAE) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,677 employees.
The shares were at 4.885 EUR on 19 November 2026, up 6.9% over 52 weeks. Its 52-week range is 4.315 EUR to 5.440 EUR: the price is 10.2% below the high and 13.2% above the low.
At a market capitalisation of 1.52B EUR, it trades at 18.1 times trailing earnings and 14.1 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 27% for FAE. It pays a dividend yielding 2.57% (it pays out 48% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Faes Farma reports return on equity of 10.7%, an operating margin of 13.0% and revenue up 17.4% year over year.
Its debt exceeds its cash by 312.50M EUR, a debt-to-equity ratio of 0.57. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 5.564 EUR is 13.9% above the current price. The next earnings report is expected on 25 February 2027.